Patients with obesity and metabolic syndrome : Weight reduction achieved through GLP-1 therapy often correlates with improvements in the characteristic dyslipidaemia of metabolic syndrome (elevated triglycerides, low HDL cholesterol, and small dense LDL particles)
As Mounjaro significantly suppresses appetite and delays gastric emptying, patients often consume considerably fewer calories and carbohydrates than previously
At Rivas Medical Weight Loss, we ensure you receive not only high-quality medication but also expert guidance to achieve and maintain your weight loss goals
Semaglutide 14mg tablet are part of the GLP-1 (glucagon-like peptide) group of diabetes medications
The question was simple
Approval (2017) FDA News Release (March 8th, 2024): FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight FDA News Release (August 15th, 2025): FDA Approves Treatment for Serious Liver Disease Known as MASH OZEMPIC (semaglutide) injection, for subcutaneous use